Venus Remedies, 526953, VENUSREM Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

516.30
20.27
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

490.36
N/A
1.10

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

0.25
11.53
0.45

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-7.98
13.11
2.28

PAT CAGR (%)

10 Years
5 Years
3 Years

-8.46
-
-24.51

P:E (Median)

8 Years
5 Years
3 Years

10.24
6.89
11.33

P:BV (Average)

8 Years
5 Years
3 Years

0.46
0.59
0.86

EV:EBITDA (Average)

8 Years
5 Years
3 Years

6.66
7.14
6.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var% Dec 22 Dec 21 Var%
Net Sales 170.19 124.75 36.42% 98.63 154.93 -36.34% 148.53 128.77 15.35% 109.45 117.44 -6.80%
Expenses 157.06 109.58 43.33% 85.16 136.68 -37.69% 127.50 121.46 4.97% 102.37 103.21 -0.81%
EBITDA 13.13 15.17 -13.45% 13.47 18.25 -26.19% 21.03 7.31 187.69% 7.08 14.23 -50.25%
EBIDTM 7.71% 12.16% 13.66% 11.78% 14.16% 5.68% 6.47% 12.12%
Other Income 2.93 1.77 65.54% 2.06 1.41 46.10% 3.24 2.47 31.17% 3.75 1.07 250.47%
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 6.21 8.77 -29.19% 7.32 7.57 -3.30% 8.06 7.36 9.51% 6.97 8.40 -17.02%
PBT 9.85 8.17 20.56% 8.21 12.09 -32.09% 16.21 2.42 569.83% 3.86 6.90 -44.06%
Tax 4.40 0.44 900.00% 3.87 1.00 287.00% 8.67 0.00 0 1.25 -0.95 -
PAT 5.45 7.73 -29.50% 4.34 11.09 -60.87% 7.54 2.42 211.57% 2.61 7.85 -66.75%
PATM 3.20% 6.20% 4.40% 7.16% 5.08% 1.88% 2.38% 6.68%
EPS 4.07 5.77 -29.46% 3.24 8.28 -60.87% 5.63 1.81 211.05% 1.95 5.86 -66.72%

Description Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var% Dec 22 Dec 21 Var%
Net Sales 167.72 139.89 19.89% 95.15 143.08 -33.50% 155.64 142.45 9.26% 116.90 124.34 -5.98%
Expenses 149.93 126.92 18.13% 84.75 128.57 -34.08% 131.03 136.91 -4.29% 108.80 111.91 -2.78%
EBITDA 17.79 12.97 37.16% 10.40 14.51 -28.33% 24.61 5.54 344.22% 8.10 12.43 -34.84%
EBIDTM 10.61% 9.27% 10.93% 10.14% 15.81% 3.89% 6.93% 10.00%
Other Income 3.05 1.79 70.39% 2.26 1.44 56.94% 3.41 2.25 51.56% 3.81 1.22 212.30%
Interest 0.06 0.00 0 0.06 0.26 -76.92% 0.00 0.00 0 0.15 0.31 -51.61%
Depreciation 6.44 8.99 -28.36% 7.55 7.80 -3.21% 8.29 7.56 9.66% 7.22 8.64 -16.44%
PBT 14.34 5.77 148.53% 5.05 7.89 -35.99% 19.73 0.23 8,478.26% 4.54 4.70 -3.40%
Tax 4.40 0.44 900.00% 3.87 1.00 287.00% 8.67 0.00 0 1.25 -0.95 -
PAT 9.94 5.33 86.49% 1.18 6.89 -82.87% 11.06 0.23 4,708.70% 3.29 5.65 -41.77%
PATM 5.93% 3.81% 1.24% 4.82% 7.11% 0.16% 2.81% 4.54%
EPS 7.43 3.99 86.22% 0.88 5.15 -82.91% 8.27 0.17 4,764.71% 2.46 4.23 -41.84%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 526.80 537.66 576.71 514.62 320.23 301.84 355.07 375.45 402.69 451.88 526.06 Net Sales Growth 0.17% -6.77% 12.07% 60.70% 6.09% -14.99% -5.43% -6.76% -10.89% -14.10% Cost Of Goods Sold 325.52 336.70 377.50 336.68 176.81 181.78 205.42 186.69 194.64 213.05 298.96 Gross Profit 201.28 200.96 199.22 177.94 143.42 120.06 149.65 188.76 208.05 238.82 227.10 GP Margin 38.21% 37.38% 34.54% 34.58% 44.79% 39.78% 42.15% 50.28% 51.67% 52.85% 43.17% Total Expenditure 472.09 476.14 507.89 467.76 277.16 267.55 311.51 328.16 323.14 364.94 392.83 Power & Fuel Cost - 4.17 3.78 3.39 3.41 3.50 3.02 3.08 2.90 3.28 3.11 % Of Sales - 0.78% 0.66% 0.66% 1.06% 1.16% 0.85% 0.82% 0.72% 0.73% 0.59% Employee Cost - 47.67 43.75 35.89 33.79 30.26 27.82 25.02 25.02 27.26 25.57 % Of Sales - 8.87% 7.59% 6.97% 10.55% 10.03% 7.84% 6.66% 6.21% 6.03% 4.86% Manufacturing Exp. - 25.46 25.48 20.63 18.35 18.98 34.28 75.01 58.94 73.60 20.75 % Of Sales - 4.74% 4.42% 4.01% 5.73% 6.29% 9.65% 19.98% 14.64% 16.29% 3.94% General & Admin Exp. - 18.63 15.01 13.76 15.22 9.79 11.86 12.20 10.85 14.36 13.81 % Of Sales - 3.47% 2.60% 2.67% 4.75% 3.24% 3.34% 3.25% 2.69% 3.18% 2.63% Selling & Distn. Exp. - 43.24 42.37 57.40 29.59 23.24 29.11 26.17 30.78 33.39 30.64 % Of Sales - 8.04% 7.35% 11.15% 9.24% 7.70% 8.20% 6.97% 7.64% 7.39% 5.82% Miscellaneous Exp. - 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.64 % Of Sales - 0.05% 0% 0% 0% 0% 0% 0% 0% 0% 0% EBITDA 54.71 61.52 68.82 46.86 43.07 34.29 43.56 47.29 79.55 86.94 133.23 EBITDA Margin 10.39% 11.44% 11.93% 9.11% 13.45% 11.36% 12.27% 12.60% 19.75% 19.24% 25.33% Other Income 11.98 10.17 8.43 17.76 3.58 4.51 1.19 3.10 0.67 0.55 0.41 Interest 0.00 0.00 0.00 12.73 13.05 25.15 35.44 35.87 36.74 40.70 29.29 Depreciation 28.56 31.37 32.58 34.28 31.05 32.95 32.73 39.32 40.47 44.74 38.61 PBT 38.13 40.33 44.67 17.62 2.55 -19.30 -23.42 -24.80 3.01 2.04 65.73 Tax 18.19 11.36 -4.32 -13.21 1.96 -1.15 3.16 -4.56 1.81 -2.51 4.78 Tax Rate 47.71% 28.17% -9.67% -32.17% -31.31% 4.07% -13.49% 18.39% 60.13% -123.04% 7.27% PAT 19.94 28.96 48.99 54.27 -8.23 -27.11 -26.58 -20.24 1.20 4.55 60.95 PAT before Minority Interest 19.94 28.96 48.99 54.27 -8.23 -27.11 -26.58 -20.24 1.20 4.55 60.95 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 3.79% 5.39% 8.49% 10.55% -2.57% -8.98% -7.49% -5.39% 0.30% 1.01% 11.59% PAT Growth -31.45% -40.89% -9.73% - - - - - -73.63% -92.53% EPS 14.88 21.61 36.56 40.50 -6.14 -20.23 -19.84 -15.10 0.90 3.40 45.49

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 535.41 555.51 600.18 548.12 339.33 321.89 372.41 400.04 418.27 463.99 541.56 Net Sales Growth -2.61% -7.44% 9.50% 61.53% 5.42% -13.57% -6.91% -4.36% -9.85% -14.32% Cost Of Goods Sold 302.76 330.99 386.98 340.79 174.31 181.95 205.08 227.07 238.51 268.94 300.00 Gross Profit 232.65 224.51 213.20 207.33 165.02 139.94 167.33 172.97 179.77 195.05 241.55 GP Margin 43.45% 40.42% 35.52% 37.83% 48.63% 43.47% 44.93% 43.24% 42.98% 42.04% 44.60% Total Expenditure 474.51 495.31 538.07 494.35 298.52 289.37 332.94 349.32 337.11 374.81 403.33 Power & Fuel Cost - 5.52 4.71 4.58 4.73 4.86 4.29 4.14 4.01 3.80 3.38 % Of Sales - 0.99% 0.78% 0.84% 1.39% 1.51% 1.15% 1.03% 0.96% 0.82% 0.62% Employee Cost - 57.05 52.33 46.02 46.02 42.10 39.31 34.27 32.44 32.36 30.45 % Of Sales - 10.27% 8.72% 8.40% 13.56% 13.08% 10.56% 8.57% 7.76% 6.97% 5.62% Manufacturing Exp. - 32.40 31.57 22.86 20.84 21.01 36.10 42.48 15.70 17.29 22.10 % Of Sales - 5.83% 5.26% 4.17% 6.14% 6.53% 9.69% 10.62% 3.75% 3.73% 4.08% General & Admin Exp. - 20.70 16.67 16.45 17.57 11.85 13.52 13.26 11.97 15.67 14.74 % Of Sales - 3.73% 2.78% 3.00% 5.18% 3.68% 3.63% 3.31% 2.86% 3.38% 2.72% Selling & Distn. Exp. - 48.40 45.80 63.64 35.05 27.60 34.65 28.10 34.48 36.75 32.65 % Of Sales - 8.71% 7.63% 11.61% 10.33% 8.57% 9.30% 7.02% 8.24% 7.92% 6.03% Miscellaneous Exp. - 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 32.65 % Of Sales - 0.05% 0% 0% 0% 0% 0% 0% 0% 0% 0% EBITDA 60.90 60.20 62.11 53.77 40.81 32.52 39.47 50.72 81.16 89.18 138.23 EBITDA Margin 11.37% 10.84% 10.35% 9.81% 12.03% 10.10% 10.60% 12.68% 19.40% 19.22% 25.52% Other Income 12.53 10.32 8.31 19.63 5.31 6.09 2.39 4.28 2.01 0.68 0.47 Interest 0.27 0.29 0.48 13.02 13.34 25.41 35.56 36.38 37.98 41.21 29.40 Depreciation 29.50 32.30 33.53 35.28 32.01 33.98 33.83 40.26 41.68 46.00 40.22 PBT 43.66 37.93 36.41 25.11 0.78 -20.77 -27.53 -21.64 3.51 2.65 69.08 Tax 18.19 11.36 -4.32 -13.21 1.96 -1.15 3.16 -4.56 1.81 -2.51 4.78 Tax Rate 41.66% 29.95% -11.86% -27.21% -24.41% 3.87% -11.48% 21.07% 51.57% -94.72% 6.92% PAT 25.47 26.57 40.72 61.77 -10.00 -28.57 -30.69 -17.08 1.70 5.16 64.30 PAT before Minority Interest 25.47 26.57 40.72 61.77 -10.00 -28.57 -30.69 -17.08 1.70 5.16 64.30 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 4.76% 4.78% 6.78% 11.27% -2.95% -8.88% -8.24% -4.27% 0.41% 1.11% 11.87% PAT Growth 40.72% -34.75% -34.08% - - - - - -67.05% -91.98% EPS 19.01 19.83 30.39 46.10 -7.46 -21.32 -22.90 -12.75 1.27 3.85 47.99

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 478.05 449.41 400.18 332.25 340.95 367.99 394.23 444.43 466.24 467.42 Share Capital 13.37 13.37 12.34 12.34 12.34 12.34 12.34 11.44 11.44 11.44 Total Reserves 464.68 436.05 374.09 319.91 328.61 355.65 381.89 432.99 454.79 455.97 Non-Current Liabilities 58.17 45.95 58.81 96.03 136.75 157.89 179.52 212.03 221.50 161.27 Secured Loans 0.00 0.00 0.00 23.92 60.88 86.02 112.69 134.55 150.91 114.28 Unsecured Loans 38.68 38.68 47.52 48.34 55.20 50.84 49.13 56.47 51.34 25.22 Long Term Provisions 8.85 7.95 7.38 6.63 5.32 4.50 4.29 3.79 3.78 3.31 Current Liabilities 72.67 82.61 87.82 215.98 254.46 222.61 193.71 177.59 157.06 207.33 Trade Payables 48.51 49.63 68.36 33.96 33.41 27.19 30.56 23.90 25.76 28.14 Other Current Liabilities 23.27 32.23 18.78 99.99 107.61 76.87 45.70 36.63 13.99 54.12 Short Term Borrowings 0.00 0.00 0.00 81.42 108.92 117.23 115.70 115.09 115.40 110.08 Short Term Provisions 0.89 0.75 0.68 0.61 4.52 1.32 1.76 1.97 1.91 14.99 Total Liabilities 608.89 577.97 546.81 644.26 732.16 748.49 767.46 834.05 844.80 836.02 Net Block 199.68 224.67 244.20 271.47 346.89 369.93 389.38 433.52 425.77 416.09 Gross Block 568.50 578.19 581.73 589.77 674.06 669.01 655.78 660.61 612.50 555.61 Accumulated Depreciation 368.82 353.52 337.53 318.30 327.17 299.08 266.40 227.09 186.73 139.52 Non Current Assets 290.57 313.57 333.08 360.33 478.57 499.96 517.54 575.53 618.72 567.61 Capital Work in Progress 26.10 25.23 25.11 24.63 64.76 64.76 66.25 80.37 78.30 67.80 Non Current Investment 0.14 0.14 0.14 0.14 0.14 0.14 28.74 28.74 28.74 28.74 Long Term Loans & Adv. 62.55 61.96 62.34 64.08 66.78 65.13 33.17 32.90 85.91 54.98 Other Non Current Assets 2.11 1.57 1.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 318.32 264.41 213.74 283.94 253.59 248.53 249.93 258.53 226.08 268.41 Current Investments 20.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 113.60 125.63 119.69 136.44 140.94 135.98 139.69 137.69 140.44 141.46 Sundry Debtors 84.92 30.41 16.44 29.78 31.39 44.15 41.91 53.88 59.37 62.80 Cash & Bank 52.57 49.97 30.24 1.44 1.28 3.64 3.15 3.04 3.52 4.38 Other Current Assets 47.09 5.25 5.70 55.72 79.98 64.77 65.18 63.91 22.76 59.77 Short Term Loans & Adv. 44.46 53.15 41.66 60.56 74.83 59.93 65.18 63.91 22.76 59.77 Net Current Assets 245.65 181.80 125.92 67.96 -0.87 25.93 56.22 80.94 69.02 61.08 Total Assets 608.89 577.98 546.82 644.27 732.16 748.49 767.47 834.06 844.80 836.02

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 460.34 440.45 400.28 323.37 332.52 361.91 388.67 437.62 456.68 461.61 Share Capital 13.37 13.37 12.34 12.34 12.34 12.34 12.34 11.44 11.44 11.44 Total Reserves 446.97 427.08 374.19 311.03 320.18 349.57 376.33 426.18 445.24 450.17 Non-Current Liabilities 58.17 45.95 58.12 95.82 136.68 158.47 179.52 212.05 221.55 161.75 Secured Loans 0.00 0.00 0.09 24.19 61.29 86.60 112.69 134.57 150.95 114.76 Unsecured Loans 38.68 38.68 46.74 47.87 54.73 50.84 49.13 56.47 51.34 25.22 Long Term Provisions 8.85 7.95 7.38 6.63 5.32 4.50 4.29 3.79 3.78 3.31 Current Liabilities 82.57 92.74 97.45 224.58 263.62 230.38 196.81 193.14 162.83 210.99 Trade Payables 50.84 50.17 71.36 36.70 36.00 29.33 29.73 25.14 29.56 31.22 Other Current Liabilities 27.23 37.76 21.10 101.70 110.30 78.47 46.16 42.71 15.96 54.70 Short Term Borrowings 3.61 4.06 4.30 85.58 112.80 121.26 119.16 123.32 115.40 110.08 Short Term Provisions 0.89 0.75 0.68 0.61 4.52 1.32 1.76 1.97 1.91 14.99 Total Liabilities 601.08 579.14 555.85 643.77 732.82 750.76 765.00 842.81 841.06 834.35 Net Block 215.96 240.94 261.68 289.37 364.45 389.20 406.18 452.48 443.65 439.46 Gross Block 603.75 612.50 616.32 623.96 707.02 702.77 686.50 679.57 641.12 587.38 Accumulated Depreciation 387.78 371.57 354.63 334.59 342.57 313.57 280.32 227.09 197.47 147.93 Non Current Assets 278.12 301.10 321.82 349.77 467.39 490.50 505.60 565.75 607.85 562.24 Capital Work in Progress 26.10 25.23 25.11 24.63 64.76 64.76 66.25 80.37 78.30 67.80 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 33.95 33.36 35.03 35.77 38.18 36.53 33.17 32.90 85.91 54.98 Other Non Current Assets 2.11 1.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 322.96 278.04 234.03 294.00 265.43 260.27 259.41 277.07 233.21 272.11 Current Investments 20.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 119.94 125.64 119.99 141.12 142.73 138.17 140.60 143.29 142.87 142.26 Sundry Debtors 76.66 38.60 32.04 30.69 38.04 47.27 47.29 61.59 63.22 64.99 Cash & Bank 53.72 50.40 31.42 2.13 2.81 3.98 3.56 7.07 3.62 4.41 Other Current Assets 52.51 5.01 5.70 55.72 81.85 70.84 67.96 65.12 23.51 60.47 Short Term Loans & Adv. 50.73 58.39 44.88 64.34 76.70 66.00 67.96 65.12 23.51 60.47 Net Current Assets 240.39 185.30 136.59 69.43 1.81 29.88 62.59 83.93 70.38 61.12 Total Assets 601.08 579.14 555.85 643.77 732.82 750.77 765.01 842.82 841.06 834.35

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity 28.05 41.00 132.34 77.75 43.65 51.58 61.77 41.91 66.76 52.56 PBT 40.33 44.67 17.62 2.55 -19.30 -23.42 -24.80 3.01 2.04 65.73 Adjustment 22.25 24.83 21.59 40.39 59.20 64.73 69.30 53.72 81.90 35.95 Changes in Working Capital -34.53 -28.50 69.69 20.37 3.75 10.27 17.27 -14.82 -17.18 -49.12 Cash after chg. in Working capital 28.05 41.00 108.89 63.31 43.65 51.58 61.77 41.91 66.76 52.56 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 23.44 14.44 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -50.81 -16.75 55.98 -4.64 -11.27 -11.48 -18.06 3.20 -67.15 -93.75 Net Fixed Assets 8.82 3.42 7.56 124.42 -5.05 -11.74 18.95 -50.18 -67.39 -93.77 Net Investments -20.13 0.00 0.00 0.00 0.00 28.60 0.00 0.00 0.00 0.00 Others -39.50 -20.17 48.42 -129.06 -6.22 -28.34 -37.01 53.38 0.24 0.02 Cash from Financing Activity 0.00 -9.13 -161.88 -72.35 -34.74 -39.61 -43.60 -45.59 -0.47 39.31 Net Cash Inflow / Outflow -22.76 15.12 26.45 0.76 -2.36 0.49 0.11 -0.48 -0.86 -1.88 Opening Cash & Equivalents 42.83 27.70 0.00 0.50 3.64 3.15 3.04 3.52 4.38 6.26 Closing Cash & Equivalent 20.07 42.83 26.45 1.26 1.28 3.64 3.15 3.04 3.52 4.38

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity 36.63 41.10 131.84 77.60 45.33 31.19 58.93 46.88 67.80 52.65 PBT 37.93 36.41 25.11 0.78 -20.77 -27.53 -21.64 3.51 2.65 69.08 Adjustment 23.33 26.33 21.89 41.56 60.72 66.24 70.61 56.41 83.56 37.21 Changes in Working Capital -24.63 -21.64 61.39 20.82 5.37 -7.52 9.96 -13.04 -18.40 -53.65 Cash after chg. in Working capital 36.63 41.10 108.39 63.16 45.33 31.19 58.93 46.88 67.80 52.65 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 23.44 14.44 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -50.83 -16.73 56.49 -4.75 -11.33 -11.48 -18.32 2.92 -67.18 -94.66 Net Fixed Assets 8.82 3.42 7.56 124.42 -5.05 -11.74 18.95 -50.18 -67.39 -93.77 Net Investments -20.13 0.00 0.00 0.00 0.00 28.60 0.00 0.00 0.00 0.00 Others -39.52 -20.15 48.93 -129.17 -6.28 -28.34 -37.27 53.10 0.21 -0.89 Cash from Financing Activity -0.57 -9.48 -162.24 -73.00 -35.17 -39.23 -44.13 -46.35 -1.42 40.06 Net Cash Inflow / Outflow -14.77 14.90 26.09 -0.15 -1.17 -19.52 -3.51 3.46 -0.79 -1.95 Opening Cash & Equivalents 43.26 28.88 1.94 2.03 3.98 0.00 7.07 3.62 4.41 6.36 Closing Cash & Equivalent 21.21 43.26 28.88 1.94 2.81 -19.52 3.56 7.07 3.62 4.41

Financial Ratios

Consolidated /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 357.63 336.21 313.10 269.21 276.25 298.16 319.42 388.42 407.48 408.51 ROA 4.88% 8.71% 9.11% -1.20% -3.66% -3.51% -2.53% 0.14% 0.54% 7.79% ROE 6.25% 11.72% 15.10% -2.44% -7.65% -6.98% -4.83% 0.26% 0.97% 14.26% ROCE 8.03% 9.55% 10.80% 1.15% -0.48% 1.75% 1.50% 5.11% 5.55% 13.40% Fixed Asset Turnover 0.94 0.99 0.88 0.51 0.45 0.54 0.57 0.63 0.77 1.02 Receivable days 39.15 14.83 16.39 34.86 45.68 44.23 46.56 51.33 49.34 40.15 Inventory Days 81.20 77.63 90.83 158.08 167.43 141.69 134.83 126.05 113.85 92.77 Payable days 53.20 57.04 55.46 42.49 37.63 31.43 27.90 25.33 24.89 20.07 Cash Conversion Cycle 67.15 35.41 51.76 150.45 175.48 154.49 153.50 152.04 138.30 112.85 Total Debt/Equity 0.08 0.09 0.12 0.65 0.86 0.82 0.78 0.74 0.68 0.62 Interest Cover 0.00 0.00 4.23 0.52 -0.12 0.34 0.31 1.08 1.05 3.24

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 344.38 329.50 313.18 262.01 269.42 293.23 314.92 382.47 399.13 403.43 ROA 4.50% 7.18% 10.30% -1.45% -3.85% -4.05% -2.12% 0.20% 0.62% 8.29% ROE 5.90% 9.85% 17.40% -3.05% -8.23% -8.18% -4.13% 0.38% 1.12% 15.38% ROCE 7.75% 7.89% 12.37% 0.90% -0.67% 1.17% 2.00% 5.35% 5.74% 14.06% Fixed Asset Turnover 0.91 0.98 0.88 0.51 0.46 0.54 0.59 0.63 0.76 0.99 Receivable days 37.87 21.48 20.89 36.97 48.37 46.34 49.67 54.45 50.42 37.72 Inventory Days 80.68 74.69 86.94 152.66 159.26 136.61 129.51 124.86 112.15 90.94 Payable days 55.69 57.31 57.86 42.82 37.91 30.30 26.74 26.74 27.25 21.28 Cash Conversion Cycle 62.86 38.86 49.96 146.80 169.72 152.65 152.44 152.57 135.32 107.37 Total Debt/Equity 0.09 0.10 0.13 0.68 0.90 0.85 0.80 0.77 0.70 0.63 Interest Cover 129.84 76.69 4.73 0.40 -0.17 0.23 0.41 1.09 1.06 3.35

Top Investors:

k.b. shekhar

pradeep kumar jain

investor education and protection fund (iepf)

Annual Reports:

News Update:

Venus Remedies secures ‘Three Star Export House’ certificate from Government of India
6th Nov 2023, 09:49 AM

To attain this prestigious Three Star status, a company must demonstrate a significant export performance, reaching a milestone of $100 million in a span of three years
Read More
Venus Remedies wins FICCI Healthcare Award 2023
1st Nov 2023, 09:52 AM

The company has won Award in the esteemed ‘Excellence in Patient Safety and Care’ category
Read More
Venus Remedies achieves market authorization for Bleomycin in United Kingdom
26th Oct 2023, 12:07 PM

This remarkable milestone not only expands the pharma giant's global presence but also underscores its commitment to advancing cancer care
Read More
Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines
16th Oct 2023, 09:49 AM

With this, Venus Remedies has secured 525 marketing approvals for its oncology products across 76 Countries
Read More
Venus Remedies expands global reach with launch of Elores in Ecuador
12th Oct 2023, 15:39 PM

Additionally, the dossier has also been submitted in around 15 countries for getting the marketing authorisations
Read More
Venus Remedies secures marketing authorization from Serbia for gemcitabine and docetaxel
20th Sep 2023, 11:29 AM

With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Read More
Venus Remedies registers with DSIR to avail custom duty exemption
14th Sep 2023, 14:10 PM

This registration with DSIR exemplifies Venus Remedies' dedication to fostering innovation and making healthcare solutions more accessible
Read More
Venus Remedies gets marketing approval from Saudi Arabia for Enoxaparin in pre-filled syringes
28th Aug 2023, 14:09 PM

The company has an annual capacity of producing more than 5 million units of Enoxaparin, a widely used anticoagulant that prevents blood clots, at its robotic line
Read More

Venus Remedies Ltd.

Pharmaceuticals & Drugs

BSE: 526953 | NSE: VENUSREM

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Venus Remedies Ltd.

Pharmaceuticals & Drugs

BSE: 526953 | NSE: VENUSREM

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: